Back to Search
Start Over
Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers
- Source :
- Clinical Cancer Research. 15:4518-4520
- Publication Year :
- 2009
- Publisher :
- American Association for Cancer Research (AACR), 2009.
-
Abstract
- A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers.(Clin Cancer Res 2009;15(14) July 2009).
- Subjects :
- Cancer Research
Phosphatase
MAP Kinase Kinase 1
Mice, Nude
Antineoplastic Agents
Breast Neoplasms
Mice, Inbred Strains
Models, Biological
Mice
Phosphatidylinositol 3-Kinases
Downregulation and upregulation
Cell Line, Tumor
Biomarkers, Tumor
medicine
Animals
Humans
PTEN
Enzyme Inhibitors
Protein kinase B
PI3K/AKT/mTOR pathway
Phosphoinositide-3 Kinase Inhibitors
biology
Chemistry
Kinase
Mammary Neoplasms, Experimental
Cancer
medicine.disease
Xenograft Model Antitumor Assays
Oncology
Cancer cell
biology.protein
Cancer research
Female
Subjects
Details
- ISSN :
- 15573265 and 10780432
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research
- Accession number :
- edsair.doi.dedup.....71dd9dc6db151e4ac90670059049752b